[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial - 01/10/24
, Allan J Pantuck, MD a, Jean-Christophe Bernhard, MD b, Michael A Morris, MD c, Viraj Master, MD d, Andrew M Scott, MD e, f, g, h, Charles van Praet, MD i, Clement Bailly, MD j, Bülent Önal, MD k, Tamer Aksoy, MD l, Robin Merkx, MD m, David M Schuster, MD n, Sze Ting Lee, MD e, f, g, h, Neeta Pandit-Taskar, MD o, p, Alice C Fan, MD q, Phillip Allman, PhD r, Karl Schmidt s, Libuse Tauchmanova, MD t, Michael Wheatcroft, PhD t, Christian Behrenbruch, DPhil t, Colin R W Hayward, MBBS t, Peter Mulders, MD uSummary |
Background |
With limitations of conventional imaging and biopsy, accurate, non-invasive techniques to detect clear-cell renal cell carcinoma in patients with renal masses remain an unmet need. 89Zr-labelled monoclonal antibody ([89Zr]Zr-girentuximab) has high affinity for carbonic anhydrase 9, a tumour antigen highly expressed in clear-cell renal cell carcinoma. We aimed to evaluate [89Zr]Zr-girentuximab PET–CT imaging for detection and characterisation of clear-cell renal cell carcinoma.
Methods |
ZIRCON was a prospective, open-label, multicentre, phase 3 trial conducted at 36 research hospitals and practices across nine countries (the USA, Australia, Canada, the UK, Türkiye, Belgium, the Netherlands, Spain, and France). Patients aged 18 years or older with an indeterminate renal mass 7 cm or smaller (cT1) suspicious for clear-cell renal cell carcinoma and scheduled for nephrectomy received a single dose of [89Zr]Zr-girentuximab (37 MBq ±10%; 10 mg girentuximab) intravenously followed by abdominal PET–CT imaging 5 days (±2 days) later. Surgery was performed no later than 90 days after administration of [89Zr]Zr-girentuximab. Blinded central review, conducted by three independent readers, determined the histology from surgical samples. The coprimary endpoints, determined for each individual reader, were the sensitivity and specificity of [89Zr]Zr-girentuximab PET–CT imaging to detect clear-cell renal cell carcinoma, with histopathological confirmation as standard of truth. Analyses were on the full analysis set of patients, defined as patients who had evaluable PET–CT imaging and a confirmed histopathological diagnosis. The trial is registered with ClinicalTrials.gov, NCT03849118, and EUDRA Clinical Trials Register, 2018-002773-21, and is closed to enrolment.
Findings |
Between Aug 14, 2019, and July 8, 2022, 371 patients were screened for eligibility, 332 of whom were enrolled. 300 patients received [89Zr]Zr-girentuximab (214 [71%] male and 86 [29%] female). 284 (95%) evaluable patients were included in the primary analysis. The mean sensitivity was 85·5% (95% CI 81·5–89·6) and mean specificity was 87·0% (81·0–93·1). No safety signals were observed. Most adverse events were not or were unlikely to be related to [89Zr]Zr-girentuximab, with most (193 [74%] of 261 events) occurring during or after surgery. The most common grade 3 or worse adverse events were post-procedural haemorrhage (in six [2%] of 261 patients), urinary retention (three [1%]), and hypertension (three [1%]). In 25 (8%) of 300 patients, 52 serious adverse events were reported, of which 51 (98%) occurred after surgery. There were no treatment-related deaths.
Interpretation |
Our results suggest that [89Zr]Zr-girentuximab PET–CT has a favourable safety profile and is a highly accurate, non-invasive imaging modality for the detection and characterisation of clear-cell renal cell carcinoma, which has the potential to be practice changing.
Funding |
Telix Pharmaceuticals.
Le texte complet de cet article est disponible en PDF.Plan
Vol 25 - N° 10
P. 1277-1287 - octobre 2024 Retour au numéro
Article précédent
- Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
- Arun A Azad, Mathias Bressel, Hsiang Tan, Mark Voskoboynik, Aneta Suder, Andrew J Weickhardt, Alexander Guminski, Roslyn J Francis, Javad Saghebi, Nattakorn Dhiantravan, Anthony M Joshua, Louise Emmett, Lisa Horvath, Declan G Murphy, Edward Hsiao, Bavanthi Balakrishnar, Peter Lin, Andrew Redfern, William Macdonald, Siobhan Ng, Sze-Ting Lee, David A Pattison, David Nadebaum, Ian D Kirkwood, Michael S Hofman, UpFrontPSMA Study Team, T Akhurst, R Alipour, L Au, P Banks, B Emerson, N Hussain, M Haskali, J Lewin, R Linklater, L Kostos, R Kashyap, P Krishanth, G Kong, A Kumar, D Murphy, P Roselt, S Sandhu, M Scalzo, B Tran, R Wallace, L Spain, H Bourke, A Milton, D Russo, M Bills, C Chew, W Hsieh, B Crouch, D Smyth, S Pandelus, H Lam, C Gan, J Goh, A Scott, U Hafeez, U Ackermann, K Young, A Poon, K Pathmaraj, G Schembri, P Roach, D Bailey, T Hung, A Asad, T Hagan, J Watts, E Campbell, W Chua, A Pal, M Crumbaker, A Nguyen, A Yam, J Chen, L Ardolino, K Kongrak, L Ratnayake
- Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial
- Zikun Peng, Huayi Li, Yunong Gao, Li Sun, Jie Jiang, Bairong Xia, Yi Huang, Yu Zhang, Yu Xia, Yuxin Zhang, Yiyang Shen, Bowen Huang, Jiayu Nie, Xinrong Chen, Xingyu Liu, Cui Feng, Zhen Li, Wei Zhang, Kangjia Tao, Qiuxue Zhang, Shican Duan, Yaheng Chen, Yeshan Chen, Wei Wang, Hong Zheng, Yudong Lu, Yi Liu, Limei Wang, Wencai Qi, Yang He, Yan Tian, NUWA Platform Research Group, Guiling Li, Ding Ma, Qinglei Gao, Ting Hu, Shaoqing Zeng, Ya Wang, Jianhua Chi, Xiaofei Jiao, Jiahao Liu, Ming Li, Yuanjia Wen, Fan Xiong, Yu Xu, Guanchen Ma, Yingjun Zhao, Yang Yu, Ruyuan Li
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?